Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2022-09-13 Earnings Release
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Onxeo publie ses résultats financiers du 1er semestre 2022 et fait le point sur ses activités" (Onxeo publishes its financial results for the first half of 2022 and provides an update on its activities). It contains detailed consolidated financial statements (Compte de résultat consolidé) for the six months ended June 30, 2022, including revenue, operating expenses, and net result, comparing them to the previous year. It explicitly states that the semi-annual accounts were established according to IFRS but were not audited. This structure—a comprehensive financial report covering a period shorter than a year (six months)—is the definition of an Interim/Quarterly Report. Although it contains management commentary (MDA elements) and governance updates, the core purpose and primary content are the financial results for the half-year period. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-09-13 French
Half yearly financial reports and audit reports/limited reviews / Half yearly financial report
Interim / Quarterly Report Classification · 1% confidence The document is a 'Half-Year Financial Report 2022' for Onxeo. It contains a detailed summary, business activity review, financial position analysis, and condensed interim consolidated financial statements (balance sheet, income statement, cash flows, and notes). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2022
2022-09-13 English
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2022' (Half-Year Financial Report 2022) and contains a detailed summary, management discussion on business evolution, financial statements (consolidated balance sheet, income statement, cash flow), and notes to the financial statements. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2022
2022-09-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 1, 2022, announcing a clinical trial update: 'Onxeo annonce l'inclusion du 1 er patient dans l'essai clinique de phase 1b/2'. It details the initiation of a clinical study for a drug (AsiDNA) in treating recurrent high-grade glioma in children. This type of announcement, focusing on operational progress, clinical trial milestones, and scientific updates, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing strategy and progress, and not just a brief notice of a report being published (which would suggest RPA/RNS), Investor Presentation (IP) is the most fitting category for detailed operational/pipeline news shared with the investment community. It is not a formal regulatory filing like 10-K or IR, nor is it a management discussion (MDA) which usually accompanies formal financial results.
2022-09-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is titled with a headline announcing a clinical study update: "High-Grade Glioma Relapse in Children: Onxeo announces the enrollment of the first patient in the phase 1b/2 clinical study...". It contains details about a clinical trial, patient enrollment milestones, and future projections (first interim results in Q1 2024). The text is structured like a formal press release, concluding with 'COMMUNIQUÉ DE PRESSE' and contact information for media and investors. This content strongly indicates an announcement of operational progress, which is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general operational update not fitting other specific categories. Since this is a specific operational/clinical update rather than a formal financial report (like 10-K or IR) or a management discussion (MDA), and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for a press release announcing significant operational news is often RNS, unless it is explicitly an Earnings Release (ER). Given the focus is purely on clinical trial enrollment, it is a significant corporate announcement. It is not a proxy statement (PSI), dividend notice (DIV), or management change (MANG). It is a press release announcing a corporate event, which fits best under Regulatory Filings (RNS) as a general announcement, or potentially ER if it were tied to a reporting period, but ER usually implies financial results. Since it's a press release announcing a clinical milestone, RNS is the safest general classification for non-financial, non-meeting related announcements.
2022-09-01 English
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document explicitly announces that Nasdaq has approved the delisting of Onxeo's shares from the First North Growth market in Copenhagen. The title and content focus entirely on the removal of the stock from a trading venue, including details about the last day of trading and the subsequent exchange of shares. This directly corresponds to the definition of a Delisting Announcement (DLST). The document length (9106 chars) is substantial enough that it is not merely an RPA, but the substantive announcement itself.
2022-08-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.